specifically developed for psoriasis
safe, effective, portable & affordable

Listed below are a few research studies that have been published in reputable medical journals in relation to UV Therapy for Psoriasis. Many more are widely available on the web and elsewhere.

"SUMMARY Psoriasis is a chronic fluctuating dermatosis with demonstrable impact on patients' quality of life. Our aim was to investigate if narrowband UVB phototherapy administered to psoriatic patients in a standardized manner leads to an improvement in patients' perceived quality of life. A total of 138 patients with psoriasis were recruited from referrals to the Skin and Cancer Foundation, Australia between January 1998 and September 2002. Patients had psoriasis inadequately controlled by topical therapies alone and no contraindications to the use of phototherapy. Patients completed a pre- and post-therapy questionnaire on quality of life parameters. The differences in mean and standard deviation of quality of life parameters were measured using a paired sample t-test based on pre- and post-phototherapy questionnaires. Ninety patients were included in the study. Forty-eight patients were excluded as they had not completed post-phototherapy questionnaires. The course of narrowband UVB phototherapy was found to significantly improve quality of life in psoriasis patients

... 'The course of narrowband UVB phototherapy was found to significantly improve quality of life in psoriasis patients... We conclude that narrowband UVB phototherapy improves quality oflife in patients with psoriasis'

Australas J Dermatol. 2006 Feb;47(1):37-40 Quality of life in psoriasis improves after standardized administration of narrowband UVB phototherapy. Lim C, Brown P.

Weblink

" The cost of treating severe psoriasis has risen dramatically, and treatment options vary widely in terms of cost and efficacy. However, little information is available on the relative costs of home phototherapy and other long-term management options, specifically in the context of managed care. A payer-perspective cost model was developed to estimate and compare the direct expenditures associated with a 30-year course of various treatments for severe psoriasis. Within two years of treatment initiation, home-administered ultraviolet B phototherapy was less costly than any of the other treatments examined, including methotrexate, psoralen plus ultraviolet A, the retinoid acitretin, and new biologic agents. In addition, the efficacy and safety profile of home ultraviolet B phototherapy make it an excellent choice for extended management. "

...'the efficacy and safety profile of home ultraviolet B phototherapy make it an excellent choice for extended management'

Home ultraviolet B phototherapy: a cost-effective option for severe psoriasis. Yelverton CB, Kulkarni AS, Balkrishnan R, Feldman SR. Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.

Weblink

Psoriasis is a common, chronic inflammatory disease that can cause as much disability as cancer, diabetes or other major medical illnesses. Traditional therapies for treating moderate-to-severe psoriasis include phototherapy, methotrexate, oral retinoids and ciclosporin. New biological treatments provide further therapeutic options, but add to the already considerable cost of managing psoriasis. Expert panels have published guidelines for the use of biological agents in managing moderate-to-severe psoriasis; however, few if any of these guidelines appropriately consider the cost-effectiveness of treatment options. When considering cost-effectiveness in addition to safety and efficacy, ultraviolet Type B phototherapy seems to be the best first-line agent for the control of moderate-to-severe psoriasis, despite a small potential for cumulative toxicity. The biologics should be considered as second-line agents alongside the traditional systemic treatments when phototherapy proves to be ineffective or is otherwise contraindicated, such as in patients with psoriatic arthritis.

...''ultraviolet Type B phototherapy seems to be the best first-line agent for the control of moderate-to-severe psoriasis'...

Cost-effectiveness of moderate-to-severe psoriasis treatment. Miller DW, Feldman SR. Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.

Weblink

UV lamps are back in stock!! and will be ready for despatch from
Tues 23 Jan.

£78.95

FREE POSTAGE